Field D J, Pearson G A
Department of Child Health, University of Leicester School of Medicine, Leicester Royal Infirmary, U.K.
J Perinat Med. 1994;22(6):565-9.
Extra corporeal membrane oxygenation (ECMO) is a novel, but invasive, form of life support developed from cardio pulmonary by pass technology. The technique has been used successfully in mature infants with severe respiratory failure since 1975. Where persistent pulmonary hypertension is a complicating problem the improved oxygenation resulting from the use of ECMO has a therapeutic role. Controversy exists, however, with regard to whether ECMO offers any advantage over more conventional life support in terms of improved survival. Descriptive data relating to cost and morbidity suggest no disadvantage from the use of ECMO. It is hoped that the current U.K. collaborative trial will clarify whether ECMO should be considered standard therapy for severe respiratory failure occurring in mature infants.
体外膜肺氧合（ECMO）是一种源自心肺旁路技术的新型但具有侵入性的生命支持形式。自1975年以来，该技术已成功应用于患有严重呼吸衰竭的成熟婴儿。在持续性肺动脉高压成为一个复杂问题的情况下，使用ECMO带来的氧合改善具有治疗作用。然而，关于ECMO在提高生存率方面是否比更传统的生命支持具有任何优势，仍存在争议。与成本和发病率相关的描述性数据表明，使用ECMO并无劣势。希望当前英国的合作试验将阐明ECMO是否应被视为成熟婴儿严重呼吸衰竭的标准疗法。
